Skip to main content
Hamburger Menu Close



Commentary: Why new COVID-19 antiviral pills are badly needed

COVID-19 pills are crucial for the treatment of patients, especially for those at high risk in the early stages of infection, says a US infectious disease professor.

Commentary: Why new COVID-19 antiviral pills are badly needed
This image provided by Pfizer shows its COVID-19 pills. Drugmaker Pfizer said Tuesday, Nov. 16, 2021, it is submitting its experimental pill for U.S. authorisation, setting the stage for a likely launch in coming weeks. (Pfizer via AP)

CHARLOTTESVILLE, Virginia: Nearly two years into the pandemic, it has become starkly clear we need better treatments for COVID-19 for people in the earlier stages of disease.

Two new antiviral drugs could soon be the first effective oral treatments for COVID-19 to help keep people out of the hospital.

An advisory committee to the United States Food and Drug Administration (FDA) plans to review the data supporting molnupiravir - a pill made by Merck and partner Ridgeback Therapeutics - on Nov 30.

And in early November, Pfizer released preliminary results for its antiviral pill, Paxlovid, another potentially promising tool for COVID-19 treatment. On Nov 16, Pfizer formally requested emergency use authorisation of the oral pill from the FDA.

If these drugs get authorised in the coming weeks, they could be an important new treatment option for people with COVID-19, especially for those at high risk in the early stages of infection.

The ability to treat COVID-19 with a pill rather than an injection or infusion means more people can be treated faster.

Molnupiravir and Paxlovid would fill a need that hasn't been met by other COVID-19 drugs, which are either difficult to administer or only suitable for patients in the hospital.

Here's a preview of why these new antiviral drugs are important, how they work and how they could be used.

Medics wearing special suits to protect against coronavirus treat patients with coronavirus at an ICU of a hospital in Volgograd, Russia, Sunday, Nov. 21, 2021. (AP Photo/Alexandr Kulikov)


Researchers have so far found just a few drugs that are effective for the treatment of COVID-19. Until now, only antiviral monoclonal antibodies could be used to treat patients who are not hospitalised.

However, these antibody drugs - which work by blocking the virus from entering cells - have to be given in a monitored setting like a doctor's office. And many patients who could benefit from monoclonal antibodies don't have access because administration sites aren't located nearby.

They are also not affordable for many people outside the US. In the US, monoclonal antibodies are free to patients under emergency use authorisation but could ultimately become far more expensive if and when they receive full approval by the FDA.

Early data suggests that both molnupiravir and Paxlovid are effective new drugs that patients can take at home to prevent complications of COVID-19 - which could be particularly beneficial for those at high risk of severe disease.

Once authorised, these pills will allow patients to be treated earlier in the course of infection, at the point when antiviral drugs are more effective. By stopping the virus from growing in the body early on, the drugs can prevent the inflammation that causes severe COVID-19.


Molnupiravir works by causing the virus to record inaccurate genetic information. SARS-CoV-2 stores its instructions for making new viruses in a strand of RNA.

Inside the cell, the virus makes copies of the RNA and then continues to make duplicates of those copies.

When a patient takes molnupiravir, the drug masquerades as one of the key molecules in RNA and gets incorporated into the strands that the virus produces. When an RNA strand containing molnupiravir gets copied in turn, the virus makes errors in the copy.

Over multiple rounds of copying, molnupiravir forces more and more mistakes until the virus is no longer able to function - a phenomenon in virology called "error catastrophe."

Paxlovid uses a different mechanism to prevent the virus from replicating. SARS-CoV-2 creates proteins that are needed to build new viruses as one long string, called a polyprotein.

But the polyproteins have to be chopped into smaller parts by a viral enzyme called a protease in order to become active.

Paxlovid blocks the virus's protease from doing this job, thereby preventing the virus from completing its life cycle.


There are currently two primary forms of treatment for COVID-19 in the US: Antiviral and anti-inflammatory medications.

Antiviral drugs stop the virus from growing in the body and are given within the first few days of symptoms to prevent severe disease. Anti-inflammatory drugs moderate the immune response and are used to help sicker patients who need oxygen.

Molnupiravir and Paxlovid were studied in separate clinical trials with similar designs. In both studies, the drugs were tested in outpatients with risk factors for severe COVID-19 who were at an early stage in their illness.

Both studies also looked at how likely patients were to either die or be hospitalised. However, neither study has yet been peer-reviewed.

Molnupiravir reduced the risk of death or hospitalisation by about 50 per cent in non-hospitalised adult patients with mild to moderate COVID-19 when treated within five days of symptom onset.

Paxlovid reduced this risk by about 89 per cent for patients treated within three days of symptoms and 85 per cent for patients treated within five days. Importantly, no patients who took either drug died in the studies.

Because the drugs were not studied head to head, it's difficult to say whether one will be better than the other in the real world. In early November, Britain became the first country to approve molnupiravir for use.

FILE - A nurse gives a shot of the Sinopharm COVID-19 vaccine developed by Beijing Institute of Biological Products Co. Ltd. to an airport worker at a health station in Nantong in east China's Jiangsu province on Jan. 29, 2021. (Chinatopix via AP, File)

Molnupiravir did not help hospitalised patients recover faster from COVID-19. It is likely that Paxlovid would also not be useful at the point of hospitalisation.

Most patients who are in the hospital with COVID-19 are sick because of unregulated inflammation and not because the virus is still replicating in their bodies.

If and when these drugs get authorised in the US, they will probably be used for the same higher-risk patients who are eligible for monoclonal antibodies today. Monoclonal antibodies may still be used, though, for pregnant people, people on dialysis and some immune-compromised patients.

The US has already purchased millions of doses of both molnupiravir and Paxlovid in anticipation of their authorisation.

However, the pills will only be useful if people also have access to cheap, fast and accurate COVID-19 tests, which are currently in short supply. If COVID-19 is diagnosed too late, patients will already be outside the window of time when antiviral drugs can be helpful.

Other antiviral drugs are in development, including an oral form of the first COVID-19 drug, remdesivir and long acting injectable monoclonal antibodies.

Researchers are also working on repurposing existing drugs to treat COVID-19. Inhaled steroids like budesonide and an antidepressant called fluvoxamine are particularly promising.

While it's exciting to see new treatments for COVID-19, prevention is still the best strategy. The COVID-19 vaccines continue to be the most effective tool for helping to end the pandemic.

Patrick Jackson is an Assistant Professor of Infectious Diseases at the University of Virginia. This commentary first appeared on The Conversation.

Source: CNA/ep